Pendal Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Pendal Group’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,747	Closed	-$323K	–	505
2017 Q2	$323K	Buy	+5,747	New	+$230K	﹤0.01%	392

Other funds holding PTLA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pendal Group's PTLA Position: Q3 2017 in Review

Pendal Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2017, closing a stake of 5,747 shares — an estimated $323K sold.

Pendal Group first reported a position in PTLA in Q2 2017 and held it in 1 quarter. The position peaked at $323K in Q2 2017. 221 funds tracked by Wall St. Rank hold PTLA as of Q3 2017.

Pendal Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Pendal Group sold 5,747 Portola Pharmaceuticals, Inc. shares in Q3 2017, an estimated $323K.
Pendal Group first reported a position in Portola Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
Pendal Group's Portola Pharmaceuticals, Inc. position peaked at $323K in Q2 2017.
221 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2017.

Based on Pendal Group's 13F filing for Q3 2017, filed 1 Nov 2017.